InterMune
AcquiredInnovative therapies in pulmonology and fibrotic diseases
Palo Alto, United States · Founded 1995
- Headquarters
- Palo Alto, California
- Employees
- 201–500
- Founded
- 1995
- Business Model
- B2B
- Website
- intermune.com
- Acquisition Date
- Aug 2014
About
InterMune was a biotechnology company focused on research, development, and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). They developed Pirfenidone, marketed as Esbriet® in the EU and Canada. The company was acquired by Roche.
Summary
InterMune is a Biotech company based in Palo Alto, United States, founded in 1995. Investors include Roche and New Enterprise Associates.
Funding History
Aug 2014
Sign up to see all 3 rounds
IPO through Acquisition — per-round amounts, valuations, and who invested in each round.
Investors
Similar Companies
China's leading blood products manufacturer
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Altos Labs combines academic science and industry development to create medicines that restore ce...
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...
Specialty pharmaceutical company
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/intermune"><img src="https://indexed.vc/api/badge/company/intermune" alt="InterMune on Indexed.vc" width="260" height="76" /></a>